These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30537755)

  • 1. Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy.
    Saigusa M; Asada K; Akamatsu T; Tanaka Y; Endo Y; Yamamoto A; Morita S; Shirai T
    Oncol Res Treat; 2019; 42(1-2):52-56. PubMed ID: 30537755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
    Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
    Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
    Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
    J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
    Takeda K; Takifuji N; Negoro S; Furuse K; Nakamura S; Takada Y; Hoso T; Hayasaka S; Nakano T; Araki J; Senba H; Iwami F; Yamaji Y; Fukuoka M; Ikegami H
    Invest New Drugs; 2007 Aug; 25(4):377-83. PubMed ID: 17351748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.
    Imai H; Kaira K; Naruse I; Kasahara N; Kamide Y; Ono A; Masuda T; Sunaga N; Minato K; Hisada T
    Anticancer Res; 2020 Mar; 40(3):1571-1578. PubMed ID: 32132059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
    Harada T; Oizumi S; Ito K; Takamura K; Kikuchi E; Kuda T; Sugawara S; Suzuki A; Maemondo M; Fujita Y; Kinoshita I; Inoue A; Hommura F; Katsuura Y; Dosaka-Akita H; Isobe H; Nishimura M;
    Oncologist; 2013; 18(4):439-45. PubMed ID: 23442308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.
    Igawa S; Takahashi T; Nakamura Y; Tsuya A; Ono A; Shukuya T; Murakami H; Endo M; Yamamoto N
    Anticancer Res; 2008; 28(6B):3855-8. PubMed ID: 19192640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
    Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y
    Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
    Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M
    Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
    Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
    Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.
    Ebata T; Shimoi T; Ishiwata T; Iwasawa S; Bun S; Yunokawa M; Yonemori K; Takiguchi Y; Tamura K
    Oncology; 2017; 93(3):177-182. PubMed ID: 28521313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
    Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
    Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
    Kurata T; Okamoto I; Tamura K; Fukuoka M
    Invest New Drugs; 2007 Oct; 25(5):499-504. PubMed ID: 17628745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.